Uptake of treatment for osteoporosis and compliance after bone density measurement in the community

被引:12
作者
Dugard, M-N [1 ]
Jones, T. J. [1 ]
Davie, M. W. J. [1 ]
机构
[1] Robert Jones & Agnes Hunt Orthopaed & Dist Hosp N, Charles Salt Res Ctr, Oswestry SY10 7AG, Shrops, England
关键词
MINERAL DENSITY; HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; ALENDRONATE THERAPY; HOME RESIDENTS; WOMEN; PERSISTENCE; IMPACT; RISK; BISPHOSPHONATES;
D O I
10.1136/jech.2008.084558
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Management of osteoporosis is imperfect because patients may not start, persist or comply with treatment. This study was aimed to identify baseline variables associated with women failing to start, persist or comply with bisphosphonate treatment. Methods 254 women > 50 years old were selected 5 years after having a bone densitometry (bone mineral density (BMD)) diagnosis of osteoporosis. At the outset, information about osteoporosis was sent to the general practitioner (GP). Women were not under pressure at the outset to start or comply, and they and their GP were unaware that follow-up studies would take place. Patient survival was identified from the National Health Service Strategic Tracing Service, prescription data from GP records and baseline data from the initial questionnaire. Persistence was defined as at least one prescription issued per year and compliance as having a medicine possession ratio of >= 80% for each of 5 years. Results 38% failed to start treatment. Failure was associated with higher BMD Z score and residence in a nursing/residential home. Half of those starting and alive at 5 years persisted with treatment, whereas only 23% achieved a medicine possession ratio of >= 80%. Persistence was associated with a lower comorbidity index and compliance with a lower BMD Z score and a fall before starting treatment. Conclusions Treatment was low, especially in nursing/residential homes where known low treatment prevalence appears to be associated with non-initiation. The degree of depression of BMD (not just low BMD) was associated with better initiation and compliance. The association of falls with compliance suggests that fall clinics may be able to play a part in improving osteoporosis management.
引用
收藏
页码:518 / 522
页数:5
相关论文
共 30 条
[1]  
[Anonymous], 1988, HLTH DEPRIVATION INE
[2]   Low bone mineral density measurements in care home residents - a treatable cause of fractures [J].
Aspray, TJ ;
Stevenson, P ;
Abdy, SE ;
Rawlings, DJ ;
Holland, T ;
Francis, RM .
AGE AND AGEING, 2006, 35 (01) :37-41
[3]   Loss of treatment benefit due to low compliance with bisphosphonate therapy [J].
Beest, F. J. A. Penning-van ;
Erkens, J. A. ;
Olson, M. ;
Herings, R. M. C. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :511-517
[4]   The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases [J].
Brankin, Eamonn ;
Walker, Mel ;
Lynch, Niall ;
Aspray, Terence ;
Lis, Yvonne ;
Cowell, Warren .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (07) :1249-1256
[5]   Factors associated with treatment initiation after osteoporosis screening [J].
Brennan, RM ;
Wactawski-Wende, J ;
Crespo, CJ ;
Dmochowski, J .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (05) :475-483
[6]   Inclusion of older women in randomized clinical trials: Factors associated with taking study medication in the fracture intervention trial [J].
Buist, DSM ;
LaCroix, AZ ;
Black, DM ;
Harris, F ;
Blank, J ;
Ensrud, K ;
Edgerton, D ;
Rubin, S ;
Fox, KM .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (09) :1126-1131
[7]   The risks of hip fracture in older people from private homes and institutions [J].
Butler, M ;
Norton, R ;
LeeJoe, T ;
Cheng, A ;
Campbell, AJ .
AGE AND AGEING, 1996, 25 (05) :381-385
[8]   The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008
[9]   Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey [J].
Carr, A. J. ;
Thompson, P. W. ;
Cooper, C. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) :1638-1644
[10]   VALIDATION OF A COMBINED COMORBIDITY INDEX [J].
CHARLSON, M ;
SZATROWSKI, TP ;
PETERSON, J ;
GOLD, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) :1245-1251